UroGen Pharma URGN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$133.23M+3.8% | -$153.49M-21.0% | -$164.64M-42.7% | -$154.97M-36.4% | -$138.43M-32.7% | ||
| $350K+2.9% | $347K-11.3% | $340K-33.7% | $340K-44.5% | $340K-52.3% | ||
| $13.52M+0.7% | $11.96M-8.8% | $12.13M-2.3% | $12.59M+12.9% | $13.42M+36.8% | ||
| -$165.74M-54.8% | -$162.44M-67.9% | -$137.74M-43.3% | -$123.13M-43.5% | -$107.06M-30.1% | ||
| $299K-11.8% | $289K-2.0% | $387K+64.0% | $396K+65.0% | $339K+98.2% | ||
| $66.83M— | $61.56M— | —— | —— | —— | ||
| —— | —— | —— | —— | $18.37M+200% | ||
| $105.09M-24.9% | $39.92M-79.5% | $8.67M-95.5% | $40.01M-85.2% | $140M-18.1% | ||
| —— | —— | -$34.6M— | —— | —— | ||
| -$166.04M-54.6% | -$162.73M-67.7% | -$138.13M-43.3% | -$123.53M-43.6% | -$107.39M-30.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does UroGen Pharma's cash flow data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.